Clinical trial
Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate
NCT00041613 is registered in ClinicalTrials.gov with Introgen Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate
- Lead sponsor
- Introgen Therapeutics
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- Not reported
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.